Cargando…
Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency
Studies on peroxisome proliferator-activated receptor (PPAR)-γ ligands have been focused on agonists. However, PPARγ activation may induce obesity and nonalcoholic fatty liver disease (NAFLD), one of the most challenging medical conditions. Here, we identified that isorhamnetin, a naturally occurrin...
Autores principales: | Zhang, Yu, Gu, Ming, Cai, Wujie, Yu, Lijing, Feng, Li, Zhang, Lu, Zang, Qingqing, Wang, Yahui, Wang, Dongshan, Chen, Hui, Tong, Qingchun, Ji, Guang, Huang, Cheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726074/ https://www.ncbi.nlm.nih.gov/pubmed/26775807 http://dx.doi.org/10.1038/srep19288 |
Ejemplares similares
-
Protopanaxatriol, a novel PPARγ antagonist from Panax ginseng, alleviates steatosis in mice
por: Zhang, Yu, et al.
Publicado: (2014) -
PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis
por: Han, Jee-Young, et al.
Publicado: (2010) -
Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates
por: González-Arceo, Maitane, et al.
Publicado: (2022) -
Identification of an irreversible PPARγ antagonist with potent anticancer activity
por: Peng, Youyi, et al.
Publicado: (2020) -
The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)